J Korean Med Assoc.  2010 Dec;53(12):1130-1138. 10.5124/jkma.2010.53.12.1130.

Strategy for establishing an effective Korean drug utilization review system

• Choi NK
• Park BJ

• KMID: 2064730
• DOI: http://doi.org/10.5124/jkma.2010.53.12.1130

Abstract

Drug utilization review (DUR) system has been defined as "structured, ongoing initiatives that interpret patterns of drug use in relation to predetermined criteria, and attempt to prevent or minimize inappropriate prescribing." This paper introduces the concept, purpose, and effective application of DUR in Korea. DUR can be classified as retrospective DUR, prospective DUR, and concurrent DUR based on the time direction of applying DUR. DUR can also be classified as quantitative DUR defined by retrospective DUR using databases including previously prescribed medicines, and qualitative DUR defined by DUR reflecting patient's clinical condition. We described the history of developing DUR in the United States and the Europe. Finally current status of DUR in Korea is described and the strategy of future settlement of DUR system in Korea is suggested.

Keyword

Drug utilization review system; Korea; Drug safety

MeSH Terms

Drug Utilization
Drug Utilization Review
Europe
Korea
United States

Reference

1. Erwin WG. The definition of drug utilization review: statement of issues. Clin Pharmacol Ther. 1991. 50:596–599.

2. Park JY. DUR progress in the implementation and ways to expand nationwide. HIRA Policy Trend. 2010. 4:23–28.

3. Park BJ. Drug utilization review. J Pharmacoepidemiol Risk Manag. 2008. 1:13–19.

4. Park BJ, Lee SJ. Background and current status of drug utilization review in the developed countries. J Korean Soc Clin Pharmacol Ther. 1999. 7:3–16.

5. Hennessy S, Soumerai SB, Lipton HL, Strom BL. Strom BL, editor. Drug utilization review. Pharmacoepidemiology. 2005. 4th ed. Chichester: John Wiley;833–841.

6. The European Drug Utilization Research Group (Euro DURG) its aims and activities [Internet]. International Society for Pharmacoepidemiology. 2010. cited 2010 Nov 3. Bethesda (MD): International Society for Pharmacoepidemiology;Available from: http://www.pharmacoepi.org/eurodurg/presentation.cfm.

7. Choi BC. Overall understanding of the drug utilization review. HIRA Policy Trend. 2009. 3:11–16.

8. Shin KS. Prospect of drug utilization review system. HIRA Policy Trend. 2009. 3:22–26.

9. Kim DS. Understanding of foreign drug utilization review systems and their policy implications. HIRA Policy Trend. 2010. 4:14–22.

10. Yeom JH, Park JS, Oh OH, Shin HT, Oh JM. Identification of inappropriate drug prescribing by computerized, retrospective DUR screening in Korea. Ann Pharmacother. 2005. 39:1918–1923.

11. Food and Drug Administration Amendments Act (FDAAA) of 2007 [Internet]. U.S. Food and Drug Administration. 2009. cited 2010 Nov 3. Silver Spring (MD): U.S. Food and Drug Administration;Available from: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/default.htm.